Search

Author/Creator Cade, Jerry

1. 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. (31st December 2020)

Authors:
Mills, Anthony; Richmond, Gary J; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Andany, Nisha; Margolis, David; Sutton, Kenneth; Wilches, Viviana; Roberts, Jeremy; McCoig, Cynthia C; Vandermeulen, Kati; Spreen, William
Journal:
Open forum infectious diseases
Issue:
Volume 7:Number 1(2020) Supplement
Page Start:
S186
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. (27th March 2016)

Authors:
Thompson, Melanie; Saag, Michael; DeJesus, Edwin; Gathe, Joseph; Lalezari, Jay; Landay, Alan L.; Cade, Jerry; Enejosa, Jeffrey; Lefebvre, Eric; Feinberg, Judith
Journal:
AIDS
Issue:
Volume 30:Number 6(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. (27th March 2016)

Authors:
Thompson, Melanie; Saag, Michael; DeJesus, Edwin; Gathe, Joseph; Lalezari, Jay; Landay, Alan L.; Cade, Jerry; Enejosa, Jeffrey; Lefebvre, Eric; Feinberg, Judith
Journal:
AIDS
Issue:
Volume 30:Number 6(2016)
Page Start:
869
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. (1st February 2022)

Authors:
Mills, Anthony; Richmond, Gary J.; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Margolis, David A.; Sutton, Kenneth C.; Wilches, Viviana; Hatch, Sarah; Roberts, Jeremy; McCoig, Cynthia; Garris, Cindy; Vandermeulen, Kati; Spreen, William R.
Journal:
AIDS
Issue:
Volume 36:Number 2(2022)
Page Start:
195
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. (1st February 2022)

Authors:
Mills, Anthony; Richmond, Gary J.; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Margolis, David A.; Sutton, Kenneth C.; Wilches, Viviana; Hatch, Sarah; Roberts, Jeremy; McCoig, Cynthia; Garris, Cindy; Vandermeulen, Kati; Spreen, William R.
Journal:
AIDS
Issue:
Volume 36:Number 2(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗